209 related articles for article (PubMed ID: 31572788)
1. Drug-Target Residence Time Affects
Lee KSS; Yang J; Niu J; Ng CJ; Wagner KM; Dong H; Kodani SD; Wan D; Morisseau C; Hammock BD
ACS Cent Sci; 2019 Sep; 5(9):1614-1624. PubMed ID: 31572788
[TBL] [Abstract][Full Text] [Related]
2. The translational value of ligand-receptor binding kinetics in drug discovery.
Liu H; Zhang H; IJzerman AP; Guo D
Br J Pharmacol; 2023 Sep; ():. PubMed ID: 37705429
[TBL] [Abstract][Full Text] [Related]
3. In vivo potency revisited - Keep the target in sight.
Gabrielsson J; Peletier LA; Hjorth S
Pharmacol Ther; 2018 Apr; 184():177-188. PubMed ID: 29024741
[TBL] [Abstract][Full Text] [Related]
4. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety.
Copeland RA
Expert Opin Drug Discov; 2010 Apr; 5(4):305-10. PubMed ID: 22823083
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain.
Lee KSS; Ng JC; Yang J; Hwang SH; Morisseau C; Wagner K; Hammock BD
Bioorg Med Chem; 2020 Nov; 28(22):115735. PubMed ID: 33007552
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the Mechanism of Epichaperome Modulation by Zelavespib: Biochemical Insights on Target Occupancy and Extended Residence Time at the Site of Action.
Sharma S; Joshi S; Kalidindi T; Digwal CS; Panchal P; Lee SG; Zanzonico P; Pillarsetty N; Chiosis G
Biomedicines; 2023 Sep; 11(10):. PubMed ID: 37892973
[TBL] [Abstract][Full Text] [Related]
7. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
Kenakin T
ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the drug-target residence time model.
Copeland RA
Expert Opin Drug Discov; 2021 Dec; 16(12):1441-1451. PubMed ID: 34210223
[No Abstract] [Full Text] [Related]
9. Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1).
Vlachodimou A; Konstantinopoulou K; IJzerman AP; Heitman LH
Biochem Pharmacol; 2020 Feb; 172():113747. PubMed ID: 31830468
[TBL] [Abstract][Full Text] [Related]
10. Structure-kinetic relationship studies of cannabinoid CB
Soethoudt M; Hoorens MWH; Doelman W; Martella A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2018 Jun; 152():129-142. PubMed ID: 29574067
[TBL] [Abstract][Full Text] [Related]
11. The importance of binding kinetics and drug-target residence time in pharmacology.
Knockenhauer KE; Copeland RA
Br J Pharmacol; 2023 May; ():. PubMed ID: 37160660
[TBL] [Abstract][Full Text] [Related]
12. Potent Phenylpyridine and Oxodihydrofuran Inhibitors of Cyclooxygenase-2: Optimization toward a Long Residence Time with Balanced Internal Energetics.
Tian G; Suarez J; Zhang Z; Connolly P; Ahn K
Biochemistry; 2021 Aug; 60(31):2407-2418. PubMed ID: 34293856
[TBL] [Abstract][Full Text] [Related]
13. Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy.
Wang G; Ji Y; Li X; Wang Q; Gong H; Wang B; Liu Y; Pan Y
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31527517
[TBL] [Abstract][Full Text] [Related]
14. Lost in translation: What's in an EC
Gabrielsson J; Peletier LA; Hjorth S
Eur J Pharmacol; 2018 Sep; 835():154-161. PubMed ID: 30036536
[TBL] [Abstract][Full Text] [Related]
15. Does In Vitro Potency Predict Clinically Efficacious Concentrations?
Jansson-Löfmark R; Hjorth S; Gabrielsson J
Clin Pharmacol Ther; 2020 Aug; 108(2):298-305. PubMed ID: 32275768
[TBL] [Abstract][Full Text] [Related]
16. Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy.
Lee KSS; Liu JY; Wagner KM; Pakhomova S; Dong H; Morisseau C; Fu SH; Yang J; Wang P; Ulu A; Mate CA; Nguyen LV; Hwang SH; Edin ML; Mara AA; Wulff H; Newcomer ME; Zeldin DC; Hammock BD
J Med Chem; 2018 May; 61(9):4271. PubMed ID: 29701466
[No Abstract] [Full Text] [Related]
17. Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex.
Chang A; Schiebel J; Yu W; Bommineni GR; Pan P; Baxter MV; Khanna A; Sotriffer CA; Kisker C; Tonge PJ
Biochemistry; 2013 Jun; 52(24):4217-28. PubMed ID: 23697754
[TBL] [Abstract][Full Text] [Related]
18. Förster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase.
Lee KS; Morisseau C; Yang J; Wang P; Hwang SH; Hammock BD
Anal Biochem; 2013 Mar; 434(2):259-68. PubMed ID: 23219719
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase.
Wu N; Hammock BD; Lee KSS; An G
J Pharmacol Exp Ther; 2020 Jul; 374(1):223-232. PubMed ID: 32238455
[TBL] [Abstract][Full Text] [Related]
20. Drug target residence time: a misleading concept.
Folmer RHA
Drug Discov Today; 2018 Jan; 23(1):12-16. PubMed ID: 28782685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
